Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and
webcast discussion regarding the positive topline results from its
pivotal clinical trial of enfortumab vedotin in locally advanced or
metastatic urothelial cancer, which were announced in a press
release earlier today. Access to the event can be obtained as
follows:

LIVE access on Thursday, March 28, 2019

6:00 a.m. Pacific Time (PT) / 9:00 a.m. Eastern Time (ET)

• Telephone 866-288-0540 (domestic) or +1 786-460-7199 (international);
  conference ID 3807860
• Webcast available at www.seattlegenetics.com
  in the Investors
  section

REPLAY access

• Telephone replay will be available until 5:00 p.m. PT on Monday, April
  1, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820
  (international); conference ID 3807860
• Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com
  in the Investors
  section

About Seattle Genetics

Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes transformative
therapies targeting cancer to make a meaningful difference in people’s
lives. ADCETRIS^® (brentuximab vedotin) utilizes the company’s
industry-leading antibody-drug conjugate (ADC) technology and is
currently approved for the treatment of multiple CD30-expressing
lymphomas. Beyond ADCETRIS, the company has established a pipeline of
novel targeted therapies at various stages of clinical testing,
including three in ongoing pivotal trials for solid tumors. Enfortumab
vedotin for metastatic urothelial cancer and tisotumab vedotin for
metastatic cervical cancer utilize our proprietary ADC technology.
Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal
trial for HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a portfolio of
proprietary immuno-oncology agents in clinical trials targeting
hematologic malignancies and solid tumors. The company is headquartered
in Bothell, Washington, and has a European office in Switzerland. For
more information on our robust pipeline, visit www.seattlegenetics.com and
follow @SeattleGenetics on Twitter.

Contacts

Investors
Peggy Pinkston
(425) 527-4160
[email protected]

Media
Monique Greer
(425) 527-4641
[email protected]